The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 2 of the 12 sources its claims cite were checked for support.
Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.
Open accessAbstract
To define glycemic thresholds for activation of glucose counterregulatory systems and for symptoms of hypoglycemia, we measured these during stepped reductions in the plasma glucose concentration (in six 10-mg/dl hourly steps) from 90 to 40 mg/dl under hyperinsulinemic clamp conditions, and compared these with the same measurements during euglycemia (90 mg/dl) under the same conditions over 6 h in 10 normal humans. Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69 +/- 2 mg/dl for epinephrine secretion, 68 +/- 2 mg/dl for glucagon secretion, 66 +/- 2 mg/dl for growth hormone secretion, and 58 +/- 3 mg/dl for cortisol secretion. In contrast, the glycemic threshold for symptoms was 53 +/- 2 mg/dl, significantly lower than the thresholds for epinephrine (P less than 0.001), glucagon (P less than 0.001), and growth hormone (P less than 0.01) secretion. Thus, the glycemic thresholds for activation of glucose counterregulatory systems during decrements in plasma glucose lie within or just below the physiologic plasma glucose concentration range, and are substantially higher than the threshold for hypoglycemic symptoms in normal humans. These findings provide further support for the concept that glucose counterregulatory systems are involved in the prevention, as well as the correction, of hypoglycemia.
Overview
CoChat Summary
TL;DR
In normal humans, stepped hyperinsulinemic hypoglycemia showed that glucose counterregulatory hormone responses begin at higher plasma glucose levels than hypoglycemic symptoms. The authors conclude that counterregulatory systems are activated within or just below the physiologic glucose range, supporting their role in preventing as well as correcting hypoglycemia.
Key findings
- Calculated arterialized venous glycemic thresholds were 69±2 mg/dl for epinephrine, 68±2 mg/dl for glucagon, 66±2 mg/dl for growth hormone, 58±3 mg/dl for cortisol, and 51±3 mg/dl for norepinephrine.
- The symptom threshold was 53±2 mg/dl, significantly lower than thresholds for epinephrine (P < 0.001), glucagon (P < 0.001), and growth hormone (P < 0.01).
- The cortisol threshold tended to exceed the symptom threshold but not significantly; the norepinephrine threshold was similar to the symptom threshold.
- Mean symptom score began to increase during the 70–60 mg/dl step and clearly exceeded control values during the 60–50 mg/dl step.
Methods
- Ten normal young adults (nine men, one woman; age 23–34 yr, mean±SD 26±3 yr) underwent two 6-h studies after an overnight fast: an experimental stepped-glucose study and a euglycemic control study.
- Under hyperinsulinemic clamp conditions, plasma glucose was lowered in six 10-mg/dl hourly steps from 90 to 40 mg/dl in the experimental study, while the control study clamped glucose at 90 mg/dl; arterialized venous samples were drawn every 10 min, and symptoms were self-scored 0–10 for 12 symptoms.
- Glycemic thresholds were calculated as the mean glucose concentration at which each parameter first exceeded the 95% confidence interval from euglycemic control data, after adjusting baseline data to zero; thresholds were compared with a t test.
Limitations
- The authors state that thresholds were determined in a small, reasonably homogeneous group of normal young adults and should not be extrapolated uncritically to other conditions.
- They note the thresholds are conservative estimates that may be lower than biologic thresholds because responses must have begun before values exceeded the 95% confidence intervals; inspection suggested epinephrine and growth hormone thresholds may be >70 mg/dl, perhaps >80 mg/dl.
- They also state that arterialized venous values may not be comparable to venous glucose under other conditions, that cortisol’s lower threshold might reflect unmeasured ACTH response delay, and that steady state was not achieved in the control study; the design could not distinguish reduced plasma glucose per se from insulin resistance induced by counterregulatory activation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 4 Not checked · 32 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69±2 mg/dl for epinephrine secretion, 68±2 mg/dl for glucagon secretion, 66±2 mg/dl for growth hormone secretion, and 58±3 mg/dl for cortisol secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the calculated glycemic thresholds for epinephrine (69±2 mg/dl), glucagon (68±2), and growth hormone (66±2 mg/dl) secretion lie just below the physiologic range.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the glycemic threshold for symptoms was 53±2 mg/dl, significantly lower than the thresholds for epinephrine (P < 0.001), glucagon (P < 0.001), and growth hormone (P < 0.01) secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the glycemic thresholds for activation of glucose counterregulatory systems are substantially higher than the threshold for hypoglycemic symptoms (53±2 mg/dl).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The glycemic threshold for an increment in plasma norepinephrine (51±3 mg/dl) was similar to that for symptoms.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Arterialized venous plasma glucose concentrations were used to calculate glycemic thresholds of 69±2 mg/dl for epinephrine secretion, 68±2 mg/dl for glucagon secretion, 66±2 mg/dl for growth hormone secretion, and 58±3 mg/dl for cortisol secretion.”
- Also stated in: § Discussion · p. 3 · plain
“the calculated glycemic thresholds for epinephrine (69±2 mg/dl), glucagon (68±2), and growth hormone (66±2 mg/dl) secretion lie just below the physiologic range.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The glycemic threshold for increments in plasma cortisol (58±3 mg/dl) was lower than those for increments in epinephrine, glucagon, or growth hormone.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“On the other hand, the glycaemic thresholds of cortisol found in the present study (3.61 _+ 0.06 mmol/1) are lower, i.e. a smaller decrease in plasma glucose is sufficient to elicit a response, as compared to previous studies [1,3] using a similar methodological approach.”
From Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans (1994) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and the glycaemic threshold for activation of glucose counter-regulatory systems (approximately 3.6-3.9mmol/l [65-70 mg/dl] [6][7][8][9])”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“It is higher than the glucose levels required to produce symptoms in non-diabetic individuals (approximately 2.8-3.1 mmol/l [50-55 mg/dl] [6-9])”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Regarding the glycaemic thresholds of glucagon, growth hormone and adrenaline, the results of the present studies confirm previous reports [1,3].”
The cited source says what the claim attributes to it.
In the citing paper
“two studies using a graded stepped hypoglycaemic clamp reported similar results [18, 19].”
From Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review (2022) · cites this paper as [19]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 2
“89±2 (90), 80±1 (80), 70±1 (70), 62±1 (60), 48±1 (50), and 43±2 (40) mg/dl.”
§ Results · p. 2
“| 180-240 | 90±2 | 9.2±0.8 | 62±2 | 5.6±0.9* |”
Citations
Cites
Immunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
Effect of Ischemia on Known Substrates and Cofactors of the Glycolytic Pathway in Brain
Lowry, O. H., Passonneau, J. V., Hasselberger, F. X., & Schulz, D. W. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51740-3 · Cited by 2,221
Hormone-fuel interrelationships during fasting.
Cahill, G. F., Herrera, M. G., Morgan, A. P., Soeldner, J. S., Steinke, J., Levy, P. L., Reichard, G. A., & Kipnis, D. M. (1966) · Journal of Clinical Investigation · doi:10.1172/jci105481 · Cited by 1,036
Dose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Colorimetric ultramicro method for the determination of free fatty acids
Novák, M. (1965) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39315-9 · Cited by 639
A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma
SCHALCH, D. S., & PARKER, M. L. (1964) · Nature · doi:10.1038/2031141a0 · Cited by 635
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., Blix, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
Role of Glucagon, Catecholamines, and Growth Hormone in Human Glucose Counterregulation
Rizza, R. A., Cryer, P. E., & Gerich, J. E. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109464 · Cited by 421
Self-citationWhite, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391
Self-citationPlasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man
WALLIN, B. G., SUNDLÖF, G., ERIKSSON, B., DOMINIAK, P., GROBECKER, H., & LINDBLAD, L. E. (1981) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1981.tb06706.x · Cited by 316
Cited by
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558
Self-citationService, F. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321707 · Cited by 503
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citationHypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Plasma Leptin and Insulin Relationships in Obese and Nonobese Humans
Dagogo-Jack, S., Fanelli, C., Paramore, D., Brothers, J., & Landt, M. (1996) · Diabetes · doi:10.2337/diab.45.5.695 · Cited by 396
Hypoglycemia in patients with type 2 diabetes mellitus
Miller, C. D., Phillips, L. S., Ziemer, D. C., Gallina, D. L., Cook, C. B., & El-Kebbi, I. M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1653 · Cited by 341
Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Segel, S. A., Paramore, D. S., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.3.724 · Cited by 337
“0 pmol kg 1 min (1)) stepped hypoglycemic clamps (29) (85, 75, 65, 55 and 45 mg/dl, 4.”
Self-citationBerne, C., Fagius, J., Pollare, T., & Hjemdahl, P. (1992) · Diabetologia · doi:10.1007/bf00399935 · Cited by 293
Holte, J. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1052 · Cited by 290
Symptoms of hypoglycaemia in people with diabetes
McAulay, V., Deary, I. J., & Frier, B. M. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00620.x · Cited by 264
Boyle, P. J., Schwartz, N. S., Shah, S. D., Clutter, W. E., & Cryer, P. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182302 · Cited by 258
Self-citationAbraham, M. B., Jones, T. W., Naranjo, D., Karges, B., Oduwole, A., Tauschmann, M., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12698 · Cited by 226
Reversibility of unawareness of hypoglycemia in patients with insulinomas.
Mitrakou, A., Fanelli, C., Veneman, T., Perriello, G., Calderone, S., Platanisiotis, D., Rambotti, A., Raptis, S., Brunetti, P., Cryer, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309163291203 · Cited by 221
Self-citationKnüppel, A., Shipley, M. J., Llewellyn, C. H., & Brunner, E. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05649-7 · Cited by 225
Boyle, P. J., Kempers, S. F., O'Connor, A. M., & Nagy, R. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332602 · Cited by 221
Hypoglycaemia and cognitive function
Warren, R. E., & Frier, B. M. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00421.x · Cited by 218
Fanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Di Vincenzo, A., Modarelli, F., Ciofetta, M., Lepore, M., Annibale, B., Torlone, E., et al. (1994) · Diabetologia · doi:10.1007/bf00399801 · Cited by 212
“It is likely that recurrent hypoglycaemic episodes increase the rate of glucose transport through the blood-brain barrier, and minimize neuroglycopaenia which normally occurs when plasma glucose concentration decreases below normal post-absorptive values [27, 28, 30 ], as suggested by studies in rats [34] and more rec…”
BackgroundMethodResultInfluentialGlucose counterregulation: prevention and correction of hypoglycemia in humans
Cryer, P. E. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.2.e149 · Cited by 198
Self-citationHerbel, G., & Boyle, P. J. (2000) · Cited by 199
Fanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Ciofetta, M., Modarelli, F., Di Vincenzo, A., Annibale, B., Lepore, M., Lalli, C., et al. (1994) · Diabetologia · doi:10.1007/bf00404337 · Cited by 193
“In accordance with previous classifications [1-3, 19], the first five symptoms were considered neuroglycopenic and the last six, autonomic.”
BackgroundResultInfluential(2011) · PubMed · Cited by 187
Sleep-Related Hypoglycemia-Associated Autonomic Failure in Type 1 Diabetes
Banarer, S., & Cryer, P. E. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1195 · Cited by 187
“0 mU kg 1 min (1)) stepped hypoglycemic clamps (hourly steps at 85, 75, 65, 55, and 45 mg/dl) (11) were performed on three occasions in random, computer-generated sequence in both groups.”
Self-citationCatecholamines and their metabolites
K»gedal, B., & Goldstein, D. S. (1988) · Journal of Chromatography B: Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83871-2 · Cited by 181
Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences
ter Braak, E. W. M. T., Evers, I. M., Willem Erkelens, D., & Visser, G. H. A. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.271 · Cited by 166
Neuroendocrine responses to hypoglycemia
Tesfaye, N., & Seaquist, E. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05820.x · Cited by 164
Hypoglycaemia in Elderly Patients with Diabetes Mellitus: Causes and Strategies for Prevention
Chelliah, A., & Burge, M. R. (2004) · Drugs & Aging · doi:10.2165/00002512-200421080-00003 · Cited by 165
SYMPTOMS OF HYPOGLYCEMIA, THRESHOLDS FOR THEIR OCCURRENCE, AND HYPOGLYCEMIA UNAWARENESS
Cryer, P. E. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70084-0 · Cited by 162
Self-citationHypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1115 · Cited by 152
“Despite the reproducibility of the glycemic thresholds for these responses to falling arterial plasma glucose concentrations from laboratory to laboratory in healthy humans (10, 11, 19, 30, 33), the fact that these thresholds are dynamic rather than static warrants emphasis.”
BackgroundNeural pathways that control the glucose counterregulatory response
Verberne, A. J. M., Sabetghadam, A., & Korim, W. S. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00038 · Cited by 167
Impaired awareness of hypoglycaemia: a review
Graveling, A. J., & Frier, B. M. (2010) · Diabetes & Metabolism · doi:10.1016/s1262-3636(10)70470-5 · Cited by 160
De Feo, P., Gallai, V, Mazzotta, G., Crispino, G., Torlone, E., Perriello, G., Ventura, M. M., Santeusanio, F., Brunetti, P., & Bolli, G. B. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113616 · Cited by 138
“Thus, it appears that the glycemic threshold for the onset of neuroglycopenia is greater than currently appreciated (3-8, 25, 26), and that, although the absolute glycemic threshold for onset of neuroglycopenia and activation of hormonal counterregulation is virtually identical, the onset of the latter follows that of…”
BackgroundMethodFreeman, R. L. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00006-0 · Cited by 160
Proceedings of a consensus development conference on standardized measures in diabetic neuropathy
Kahn, R. (1992) · Muscle & Nerve · doi:10.1002/mus.880151014 · Cited by 134
Widom, B., & Simonson, D. C. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-12-904 · Cited by 130
Torlone, E., Fanelli, C. G., Rambotti, A. M., Kassi, G., Modarelli, F., Vincenzo, A. D., Epifano, L., Ciofetta, M., Pampanelli, S., Brunetti, P., et al. (1994) · Diabetologia · doi:10.1007/bf00417697 · Cited by 136
“In accordance with previous classifications [19, 20 ], the E. Torlone et al.: Monomeric insulin in IDDM”
ResultPramming, S., Thorsteinsson, B., STIGSBY, B., & Binder, C. (1988) · BMJ · doi:10.1136/bmj.296.6623.665 · Cited by 123
Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes.
Fanelli, C. G., Paramore, D. S., Hershey, T. G., Terkamp, C., Ovalle, F., Craft, S., & Cryer, P. E. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1920 · Cited by 118
Self-citationValidation of home blood glucose meters with respect to clinical and analytical approaches
Brunner, G. A., Ellmerer, M., Sendlhofer, G., Wutte, A., Trajanoski, Z., Schaupp, L., Quehenberger, F., Wach, P., Krejs, G. J., & Pieber, T. R. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.585 · Cited by 119
“was modified by constant insulin infusion (1 mU • kg"(1) • min"(1)) and by variable glucose infusion using the stepwise hypoglycemic-hyperinsulinemic clamp method (15).”
MethodDraelos, M. T., Jacobson, A. M., Weinger, K., Widom, B., Ryan, C. M., Finkelstein, D. M., & Simonson, D. C. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80397-0 · Cited by 139
INFLUENCE OF SYMPATHETIC NERVOUS SYSTEM ON HYPOGLYCAEMIC WARNING SYMPTOMS
Heller, S. R., Herbert, M., Macdonald, I. A., & Tattersall, R. B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92382-8 · Cited by 116
Hypoglycemia Unawareness in IDDM
Cryer, P. E. (1993) · Diabetes Care · doi:10.2337/diacare.16.3.40 · Cited by 113
“It is now well documented that there is an order to the responses to hypoglycemia (33,34).”
BackgroundSelf-citationAltered responses to hypoglycemia of healthy elderly people
Meneilly, G. S., Cheung, E., & Tuokko, H. A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.8200936 · Cited by 122
Segel, S. A., Fanelli, C. G., Dence, C. S., Markham, J., Videen, T. O., Paramore, D. S., Powers, W. J., & Cryer, P. E. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1911 · Cited by 116
“0 pmol z kg(21) z min(21)) stepped hypoglycemic clamps (25) were performed, and 20% dextrose was infused at variable rates, based on plasma glucose measurements every 5 min, to clamp plasma glucose concentrations at nominal levels of 85 mg/dl (4.”
Self-citationHindbrain catecholamine neurons control multiple glucoregulatory responses
Ritter, S., Dinh, T. T., & Li, A. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.036 · Cited by 117
MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia
Kittah, N. E., & Vella, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1062 · Cited by 107
Zhou, H., Tran, P. O. T., Yang, S., Zhang, T., LeRoy, E., Oseid, E. A., & Robertson, R. P. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1482 · Cited by 113
Claessens, M., Saris, W. H. M., & van Baak, M. A. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114507886314 · Cited by 110
“How carbohydrate co-ingestion would affect protein-induced glucagon secretion is likely to depend on the carbohydrate dosage, since glucagon secretion is controlled by both plasma amino acids and the change in glucose concentrations((33)).”
BackgroundPHYSIOLOGY OF GLUCOSE COUNTERREGULATION TO HYPOGLYCEMIA
Bolli, G. B., & Fanelli, C. G. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70083-9 · Cited by 99
Abraham, M. B., Karges, B., Dovč, K., Naranjo, D. M., Arbeláez, A. M., Mbogo, J., Javelikar, G., Jones, T. W., & Mahmud, F. H. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13443 · Cited by 135
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Dütting, E. D., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 104
“Abnormal cardiac repolarization ↑ catecholamines (hypokalaemia) [14,50-52]”
BackgroundPrimacy of liver glucosensors in the sympathetic response to progressive hypoglycemia.
Donovan, C. M., Hamilton-Wessler, M., Halter, J. B., & Bergman, R. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2863 · Cited by 92
Clowes, J. A., Robinson, R. T. C. E., Heller, S. R., Eastell, R., & Blumsohn, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8660 · Cited by 92
Carbohydrate to protein ratio in food and cognitive performance in the morning
Fischer, K., Colombani, P., Langhans, W., & Wenk, C. (2002) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00676-x · Cited by 101
“Since cognitive functions change shortly after a prevailing metabolic state is disrupted and counterregulation begins [8,44], changes in the GIR may be closer related to changes in cognitive functions than changes in glucose concentration.”
BackgroundHøjlund, K., Wildner‐Christensen, M., Eshøj, O., Skjærbæk, C. B., Holst, J. J., Koldkjær, O. G., Jensen, D. M., & Beck‐Nielsen, H. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.1.e50 · Cited by 101
“3 mmol/l (27, 33, 40), in which some subjects experience hypoglycemic symptoms and stop the fast (35, 36).”
BackgroundDavis, S. N., Shavers, C., & Costa, F. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e1054 · Cited by 86
“1) As previously described (32), the glycemic threshold for a given parameter was the glucose level when the value of a parameter exceeded the 95% confidence limit observed for that parameter at the corresponding time point in euglycemic control experiments.”
BackgroundMethodResultInfluentialAn Overview of Hypoglycemia in the Critically Ill
Lachérade, J.-C., Jacqueminet, S., & Preiser, J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300603 · Cited by 96
Nocturnal Blood Glucose Control in Type I Diabetes Mellitus
Bolli, G. B., Perriello, G., Fanelli, C. G., & Feo, P. D. (1993) · Diabetes Care · doi:10.2337/diacare.16.3.71 · Cited by 98
Impact of Hypoglycemia on Brain Metabolism During Diabetes
Rehni, A. K., & Dave, K. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1044-6 · Cited by 89
Accuracy of home blood glucose meters during hypoglycemia
Trajanoski, Z., Brunner, G. A., Gfrerer, R., Wach, P., & Pieber, T. R. (1996) · Diabetes Care · doi:10.2337/diacare.19.12.1412 · Cited by 85
“After a 60-min period of equilibration, a hypoglycemic-hyperinsulinemic clamp was started according to a published protocol (9).”
MethodIncrease in Weight in All Birth Cohorts in a General Population
Jacobsen, B. K., Njølstad, I., Thune, I., Wilsgaard, T., Løchen, M., & Schirmer, H. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.466 · Cited by 85
The effect of starvation on insulin-induced glucose disposal and thermogenesis in humans
Mansell, P. I., & Macdonald, I. A. (1990) · Metabolism · doi:10.1016/0026-0495(90)90009-2 · Cited by 84
Insulin therapy and hypoglycaemia: the size of the problem
Fanelli, C. G., Porcellati, F., Pampanelli, S., & Bolli, G. B. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.514 · Cited by 86
Preventing hypoglycaemia: what is the appropriate glucose alert value?
Cryer, P. E. (2009) · Diabetologia · doi:10.1007/s00125-008-1205-7 · Cited by 77
“Notably, in his thorough analysis of the methods prior to 1993, Heine [17] specifically endorsed the method used to calculate the glycaemic thresholds for glucose counter-regulatory and symptomatic responses to hypoglycaemia in two of the three studies [ 7 , 8] that generated the glycaemic thresholds mentioned earlier…”
MethodSelf-citationThe clinical impact of inpatient hypoglycemia
Brutsaert, E. F., Carey, M., & Zonszein, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.03.002 · Cited by 78
“(Cryer, 2013;Mitrakou et al., 1991; Schwartz et al., 1987; Service, 1995).”
BackgroundLlU, D., MOBERG, E., KOLLIND, M., LINS, P.-E., & ADAMSON, U. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1123 · Cited by 76
O-GlcNAcylated p53 in the liver modulates hepatic glucose production
Gonzalez-Rellan, M. J., Fondevila, M. F., Fernandez, U., Rodríguez, A., Varela‐Rey, M., Veyrat‐Durebex, C., Seoane, S., Bernardo‐Seisdedos, G., Lopitz‐Otsoa, F., Fernández‐Ramos, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25390-0 · Cited by 80
Defining hypoglycaemia: what level has clinical relevance?
Frier, B. M. (2009) · Diabetologia · doi:10.1007/s00125-008-1209-3 · Cited by 71
“Why was this level chosen? The ADA Workgroup argued that this is the glycaemic level at which hormonal counter-regulation is activated in non-diabetic adults [4, 5], and that antecedent hypoglycaemia of this modest degree can reduce the secretion of the counterregulatory hormones glucagon and adrenaline (epinephrine)…”
BackgroundFanelli, C. G., Dence, C. S., Markham, J., Videen, T. O., Paramore, D. S., Cryer, P. E., & Powers, W. J. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1444 · Cited by 70
Self-citationDisorders of glucose metabolism: post mortem analyses in forensic cases–part II
Mußhoff, F., Heß, C., & Madea, B. (2010) · International Journal of Legal Medicine · doi:10.1007/s00414-010-0510-0 · Cited by 71
Hepburn, D. A., Patrick, A. W., Brash, H. M., Thomson, I., & Frier, B. M. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01533.x · Cited by 66
McGregor, V. P., Banarer, S., & Cryer, P. E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00447.2001 · Cited by 56
Self-citationTrajanoski, Z., Brunner, G. A., Schaupp, L. A., Ellmerer, M., Wach, P., Pieber, T. R., Kotanko, P., & Skrabal, F. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1114 · Cited by 67
Landstedt‐Hallin, L., Adamson, U., & Lins, P. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.6002 · Cited by 76
“6 mmol/L, the earliest physiological response in healthy subjects is the suppression of insulin secretion (15).”
BackgroundThe physiology and pathophysiology of the neural control of the counterregulatory response
Beall, C., Ashford, M. L., & McCrimmon, R. J. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00531.2011 · Cited by 63
“7 mM (43, 84, 105) and are initiators of the adaptive response to hypoglycemia (such as during prolonged starvation), as the glucose-raising actions are much slower in onset (several hours).”
BackgroundPage, K. A., Arora, J., Qiu, M., Relwani, R., Constable, R. T., & Sherwin, R. S. (2008) · Diabetes · doi:10.2337/db08-1224 · Cited by 65
Glucose homeostasis in the newborn
Hume, R., Burchell, A. N., Williams, F. L. R., & Koh, D. K. M. (2004) · Early Human Development · doi:10.1016/j.earlhumdev.2004.10.005 · Cited by 65
Hussain, K., Hindmarsh, P., & Aynsley-Green, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030135 · Cited by 64
Hypoglycemia in everyday life after gastric bypass and duodenal switch
Abrahamsson, N., Engström, B. E., Sundbom, M., & Karlsson, F. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0821 · Cited by 70
Jung, H. S., Kim, H. I., Kim, M. J., Yoon, J. W., Ahn, H. Y., Cho, Y. M., Oh, K., Joo, K. W., Lee, J. G., Kim, S. Y., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0067 · Cited by 68
“…as plasma glucose levels (cid:5) 70mg/dL 32 because the glycemic threshold for activation of glucagon and epinephrine secretion as glucose levels decline was 65–70 mg/ dL 33,34 and because antecedent plasma glucose levels 70mg/dL reduced sympathoadrenal responses to subsequent hypoglycemia.”
de Vos, P., Vegter, D., de Haan, B. J., STRUBBE, J. H., Bruggink, J. E., & Schilfgaarde, R. V. (1996) · Diabetes · doi:10.2337/diab.45.8.1102 · Cited by 67
“It is unlikely that endogenous insulin has contributed to the patterns of uptake of the infused insulin since insulin administration is associated with a decrease of the blood glucose levels, which suppresses the endogenous production of insulin (24,25).”
BackgroundHypoglycemia: Definition, Clinical Presentations, Classification, and Laboratory Tests
Field, J. B. (1989) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30387-6 · Cited by 61
Mathematical models of energy homeostasis
Pattaranit, R., & van den Berg, H. A. (2008) · Journal of The Royal Society Interface · doi:10.1098/rsif.2008.0216 · Cited by 61
Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes.
de Galan, B. E., Schouwenberg, B. J. J. W., Tack, C. J., & Smits, P. (2006) · PubMed · Cited by 82
Counterregulatory hormonal responses to hypoglycemia during pregnancy
Rosenn, B., Miodovnik, M., Khoury, J. C., & Siddiqi, T. A. (1996) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00495-5 · Cited by 62
Rickels, M. R., Schutta, M. H., Mueller, R., Kapoor, S. C., Markmann, J. F., Naji, A., & Teff, K. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2426 · Cited by 59
Hypoglycemia in diabetes: common, often unrecognized.
Gabriely, I., & Shamoon, H. (2004) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.71.4.335 · Cited by 60
Pampanelli, S., Fanelli, C. G., Lalli, C., Ciofetta, M., Sindaco, P., Lepore, M., Modarelli, F., Rambotti, A. M., Epifano, L., Vincenzo, A. D., et al. (1996) · Diabetologia · doi:10.1007/bf00418539 · Cited by 61
“In accordance with previous classifications [ 18 , 19], the first five symptoms were considered neuroglycopenic and the last six autonomic.”
Deficient Counterregulatory Hormone Responses during Hypoglycemia in a Patient with Insulinoma*
DAVIS, M. R., & Shamoon, H. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-4-788 · Cited by 56
Cady, G., Landeryou, T., Garratt, M., Kopchick, J. J., Qi, N., García-Galiano, D., Elias, C. F., Myers, M. G., Miller, R. A., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.03.001 · Cited by 52
“Decreases in glucose levels are detected by glucose-sensing neurons that are found in several brain regions including the VMH, the LHA, the ARH, as well as in several hindbrain regions [37,38].”
BackgroundPrevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes
Rossetti, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2008) · Diabetes Care · doi:10.2337/dc08-s227 · Cited by 60
Elman, I., & Breier, A. F. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00776-5 · Cited by 56
Sato, Y., Nishikawa, M., Shinkai, H., & Sukegawa, E. (1991) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(91)90130-6 · Cited by 54
Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data
Lehmann, V., Föll, S., Maritsch, M., van Weenen, E., Kraus, M., Lagger, S., Odermatt, K., Albrecht, C., Fleisch, E., Zueger, T., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2290 · Cited by 53
“…heart rate, decreased heart rate variability, and increased tonic component of elec-trodermal activity with hypoglycemia re-fl ected the physiological stress response to hypoglycemia, such as tachycardia and sweating (2,13,14) (see Supplementary Table 1 for further explanation of the features).”
BackgroundJacobson, L., Ansari, T., & McGuinness, O. P. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00383.2005 · Cited by 53
Hyperinsulinism and Its Interaction With Hyperandrogenism in Polycystic Ovary Syndrome
Sozen, I., & Arici, A. M. (2000) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200005000-00026 · Cited by 55
Li, T., & Gleeson, M. (2005) · European Journal of Applied Physiology · doi:10.1007/s00421-005-0024-5 · Cited by 58
“The plasma glucose level at the end of EX2 was as low as 3.75±0.22 mM (Fig. 3a), reaching the threshold for inducing elevated plasma adrenaline (3.8±0.1 mM) and GH (3.7±0.1 mM) secretion ( Schwartz et al. 1987 ).”
Influential
Metadata
- Authors
- Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E.
- Affiliations
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1987-03-01
- Volume
- 79
- Issue
- 3
- Pages
- 777-781
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC424197
- OpenAlex
- W2087707740
- Semantic Scholar
- 04e9668073ba5c3c773cd60e2a3f9b07a954bf4b
- Cited by
- 394
- References
- 38
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 14 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 13 · 2017: 13 · 2016: 10 · 2015: 12 · 2014: 12 · 2013: 13 · 2012: 12
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60am020579-08, 2r01am027085-06)
- National Center for Research Resources (RR.00036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- hypoglycemia, glycemic thresholds, glucose counterregulation, hypoglycemic symptoms, epinephrine secretion, glucagon secretion, growth hormone secretion, cortisol secretion, hyperinsulinemic-euglycemic clamp, plasma glucose, hypoglycemia prevention
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Epinephrine, Fatty Acids, Nonesterified, Female, Glucagon, Humans, Hydrocortisone, Hydroxybutyrates, Hypoglycemia, Insulin, Lactates, Male, Norepinephrine, Growth Hormone, Lactic Acid, 3-Hydroxybutyric Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.